- Home
- WSBF vs SLN Comparison
WSBF vs SLN Comparison
Compare WSBF & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSBF
- SLN
- Stock Information
- Founded
- WSBF 1921
- SLN 1994
- Country
- WSBF United States
- SLN United Kingdom
- Employees
- WSBF N/A
- SLN N/A
- Industry
- WSBF Savings Institutions
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- WSBF Finance
- SLN Health Care
- Exchange
- WSBF Nasdaq
- SLN Nasdaq
- Market Cap
- WSBF 263.4M
- SLN 227.2M
- IPO Year
- WSBF N/A
- SLN N/A
- Fundamental
- Price
- WSBF $14.77
- SLN $5.69
- Analyst Decision
- WSBF
- SLN Buy
- Analyst Count
- WSBF 0
- SLN 5
- Target Price
- WSBF N/A
- SLN $32.60
- AVG Volume (30 Days)
- WSBF 52.4K
- SLN 54.4K
- Earning Date
- WSBF 10-21-2025
- SLN 08-07-2025
- Dividend Yield
- WSBF 4.06%
- SLN N/A
- EPS Growth
- WSBF 82.58
- SLN N/A
- EPS
- WSBF 1.13
- SLN N/A
- Revenue
- WSBF $134,196,000.00
- SLN $27,169,000.00
- Revenue This Year
- WSBF N/A
- SLN N/A
- Revenue Next Year
- WSBF N/A
- SLN N/A
- P/E Ratio
- WSBF $13.07
- SLN N/A
- Revenue Growth
- WSBF 1.23
- SLN 22.28
- 52 Week Low
- WSBF $11.61
- SLN $1.97
- 52 Week High
- WSBF $16.86
- SLN $20.48
- Technical
- Relative Strength Index (RSI)
- WSBF 62.07
- SLN 55.97
- Support Level
- WSBF $14.63
- SLN $4.77
- Resistance Level
- WSBF $15.29
- SLN $5.29
- Average True Range (ATR)
- WSBF 0.28
- SLN 0.40
- MACD
- WSBF 0.02
- SLN 0.03
- Stochastic Oscillator
- WSBF 57.38
- SLN 77.64
About WSBF Waterstone Financial Inc. (MD)
Waterstone Financial Inc is a holding company. Through its subsidiaries, it operates in two reportable segments: Community Banking and Mortgage Banking. The Community Banking segment provides consumer and business banking products and services to customers, which include various types of loans, deposits, and personal investment services. The Mortgage Banking segment involves residential mortgage loans for the primary purpose of sale in the secondary market. The vast majority of its revenue comes from the Community Banking segment.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.